Q: Hello Folks:
Could you please give me your view on Merck and Company (which along with Smith- Kline) has had problems executing new drugs (eg. lung cancer medications) in their pipelines. I also have previously owned Gilead, whose new HIV drug was reduced in value because of government pricing restrictions. My other health care equities are Johnson and Johnson and Knight Therapeutics. Do you think there are better health industry options (with decent dividends and growth potential) in the U.S. other than companies such as Merck, Gilead etc. or should one look to another sector.
Thanks for everything
brian
Could you please give me your view on Merck and Company (which along with Smith- Kline) has had problems executing new drugs (eg. lung cancer medications) in their pipelines. I also have previously owned Gilead, whose new HIV drug was reduced in value because of government pricing restrictions. My other health care equities are Johnson and Johnson and Knight Therapeutics. Do you think there are better health industry options (with decent dividends and growth potential) in the U.S. other than companies such as Merck, Gilead etc. or should one look to another sector.
Thanks for everything
brian